A phase 1/2 study of inlexisertib (DCC-3116) in combination with ripretinib for patients with advanced gastrointestinal stromal tumors: Expansion cohort design

Pooled safety of vimseltinib in patients with tenosynovial giant cell tumor who received no prior colony-stimulating factor 1 receptor inhibitor therapy

Time until definitive deterioration in patient-reported outcomes with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib who harbor KIT exon 11 + 17/18 mutations: Exploratory analysis from INTRIGUE